| Literature DB >> 33693253 |
Abstract
Background: There is scant clinical data of electrolyte analyses in the pleural fluid under heart failure (HF) pathophysiology. Methods andEntities:
Keywords: Body fluid; Chloride; Electrolyte; Heart failure; Pleural effusion
Year: 2020 PMID: 33693253 PMCID: PMC7932818 DOI: 10.1253/circrep.CR-20-0018
Source DB: PubMed Journal: Circ Rep ISSN: 2434-0790
Clinical Characteristics of the Study Patients (n=15)
| Mean±SD | 85±11 |
| Range | 62–99 |
| 8 (53) | |
| Ischemic or dilated cardiomyopathy | 5 (33) |
| Valvular disease | 4 (26) |
| Hypertension | 3 (20) |
| Hypertrophic cardiomyopathy | 1 (7) |
| Arrhythmia | 1 (7) |
| Congenital heart disease | 1 (7) |
| 51.4±17.8 | |
| 8 (53) | |
| 10 (67) | |
| Mean±SD | 1.27±0.55 |
| Range | 0.41–2.32 |
| Mean±SD | 3.41±0.54 |
| Range | 2.4–4.7 |
| Data not available | 5 (33) |
| Using cardiovascular medication | 10 (67) |
| Loop diuretics | 8 (53) |
| Thiazide diuretics | 1 (7) |
| MRA | 7 (47) |
| ACEI/ARB | 3 (20) |
| β-blockers | 3 (20) |
| Calcium antagonists | 3 (20) |
| Vasopressin antagonist | 4 (26) |
| Bilateral leg edema around or above the ankle | 15 (100) |
| Bilateral pulmonary rales beyond the basal lung | 9 (60) |
| ≥500 | 10 (67) |
| 300–500 | 2 (13) |
| 200–300 | 2 (13) |
| 100–200 | 1 (7) |
| 3 (20) | |
Unless specified otherwise, data presented as n (%). ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin II receptor blocker; CRP, C-reactive protein; HF, heart failure; LVEF, left ventricular ejection fraction; MRA, mineralocorticoid receptor antagonist.
Clinical Picture at Admission and After Decongestive Therapy in Patients With HF-Associated Pleural Effusion
| Patient | Age (years)/ | Primary diagnosis | ECG | EF (%) | Before decongestion therapy | After decongestion therapy | X-ray CT | Clinical course | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Rales | Leg edema | BW (kg) | BNP (pg/mL) | Rales | Leg edema | ΔBW (kg) | BNP (pg/mL) | US-PLE | |||||||
| 1 | 91/F | Systolic HF | Af | 24 | Yes | Yes | NA | 598 | NA | NA | NA | NA | NA | NA | Transfer |
| 2 | 91/F | Systolic HF | Af | 47 | Yes | Yes | 33.6 | 897 | No | No | −1.4 | 294 | Absent | No | Improved |
| 3 | 85/F | Systolic HF | Af | 49 | No | Yes | 69.3 | 771 | No | No | −3.9 | 146 | Absent | No | Improved |
| 4 | 86/F | AR | SR | 53 | No | Yes | 36 | 589 | No | No | −1.4 | 387 | Reduced | NA | Improved |
| 5 | 91/M | HHD | SR | 80 | Yes | Yes | 58.4 | 471 | No | No | −9.3 | 224 | Absent | No | Improved |
| 6 | 91/M | HHD | SR | 64 | Yes | Yes | 57.9 | 806 | Yes | No | −5.6 | 383 | Absent | No | Improved |
| 7 | 83/M | Arrhythmia | Af | 60 | Yes | Yes | NA | 576 | No | No | NA | 56 | Reduced | No | Improved |
| 8 | 92/M | HCM | Af | 48 | No | Yes | NA | 958 | NA | NA | NA | NA | NA | No | Died |
| 9 | 99/F | AS | Af | 40 | Yes | Yes | 38.2 | 2,864 | NA | NA | NA | 1,553 | NA | No | Died |
| 10 | 62/M | CHD | SR | 57 | No | Yes | 46.2 | 631 | No | No | −4.8 | 123 | Absent | No | Improved |
| 11 | 69/F | MS | Af | 54 | No | Yes | 33.3 | 132 | No | No | −2.3 | 78 | Reduced | No | Improved |
| 12 | 93/M | HHD | SR | 81 | Yes | Yes | 76.9 | 211 | NA | NA | NA | NA | NA | NA | Transfer |
| 13 | 85/F | AS | Af | 60 | No | Yes | 39.5 | 237 | No | No | −4.2 | 97 | Absent | NA | Improved |
| 14 | 86/M | Systolic HF | Af | 39 | Yes | Yes | 43.6 | 460 | No | No | −6 | 179 | Absent | NA | Improved |
| 15 | 65/M | Systolic HF | Af | 15 | Yes | Yes | 50.2 | 596 | Yes | No | −5.7 | 92 | Absent | No | Improved |
Systolic heart failure (HF) included ischemic and dilated cardiomyopathy. Af, atrial fibrillation; AR, aortic regurgitation; AS, aortic stenosis; BNP, B-type natriuretic peptide; BW, body weight; CHD, congenital heart disease; CT, computed tomography; ECG, electrocardiography; EF, ejection fraction; F, female; HCM, hypertrophic cardiomyopathy; HHD, hypertensive heart disease; M, male; MS, mitral stenosis; NA, not available; SR, sinus rhythm; US-PLE, ultrasound pleural effusion.
Biochemical Measurements of Blood Serum and Pleural Fluid Samples in Patients With HF-Associated Pleural Effusion
| Patient | Total protein | Lactate dehydrogenase | Albumin | Other peripheral blood | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Serum | PlF | PlF/ | Serum | PlF | PlF/ | Serum | PlF | Serum-PlF | WBC | CRP | ADA | TB | |
| 1 | 6.8 | 2.1 | 0.31 | 207 | 72 | 0.35 | 3.3 | 1.2 | 2.1 | 6,930 | 2.36 | NA | Negative |
| 2 | 5.2 | 2.2 | 0.42 | 161 | 182 | 1.13A | 2.4 | 1.2 | 1.2B | 9,310 | 18.3 | NA | Negative |
| 3 | 6.2 | 2.7 | 0.44 | 160 | 81 | 0.51 | 2.7 | 1.4 | 1.3 | 5,540 | 1.63 | NA | Negative |
| 4 | 6.8 | 2.6 | 0.38 | 245 | 159 | 0.65A | 3.7 | 1.6 | 2.1 | 4,170 | 0.1 | NA | Negative |
| 5 | 5.6 | 1.7 | 0.3 | 295 | 96 | 0.33 | 3.4 | 1.1 | 2.3 | 7,490 | 0.5 | 3.2 | Negative |
| 6 | 5.7 | 2.5 | 0.44 | 245 | 166 | 0.68A | 3.6 | 1.8 | 1.8 | 8,820 | 0.03 | 8.6 | Negative |
| 7 | 5.8 | 2.5 | 0.43 | 173 | 67 | 0.39 | 3.4 | 1.5 | 1.9 | 6,830 | 0.69 | 16 | Negative |
| 8 | 6.7 | 2.9 | 0.43 | 322 | 352A | 1.09A | 3.6 | 1.7 | 1.9 | 3,420 | 2.93 | 10.5 | Negative |
| 9 | 6.5 | 1.8 | 0.28 | 182 | 119 | 0.65A | 3.2 | 1.1 | 2.1 | 7,010 | 4.45 | 10.4 | Negative |
| 10 | 5.9 | 2.1 | 0.36 | 253 | 93 | 0.37 | 3.3 | 1.4 | 1.9 | 7,230 | 6.56 | 10.2 | Negative |
| 11 | 8 | 1.7 | 0.21 | 265 | 62 | 0.23 | 4.7 | 1.1 | 3.6 | 7,430 | 6.86 | 6.8 | Negative |
| 12 | 6.7 | 2.6 | 0.39 | 234 | 108 | 0.46 | 2.9 | 1.4 | 1.5 | 4,210 | 0.36 | 13 | Negative |
| 13 | 6.7 | 1 | 0.15 | 261 | 112 | 0.43 | 4 | 0.1 | 3.9 | 3,280 | 0.02 | 8.5 | Negative |
| 14 | 6.6 | 1 | 0.15 | 189 | 64 | 0.34 | 3.4 | 1.1 | 2.3 | 4,910 | 0.14 | 6 | Negative |
| 15 | 5.8 | 1.1 | 0.19 | 295 | 66 | 0.22 | 3.5 | 0.8 | 2.7 | 7,340 | 0.21 | 4.4 | Negative |
AFulfills Light’s criteria. BFulfills the serum-pleural fluid (PlF) albumin gradient. ADA, adenosine deaminase activity; PCR, polymerase chain reaction; TB, tuberculosis; WBC, white cell count. Other abbreviations as in Tables 1,2.
Pleural Effusion-Serum Electrolyte Gradient in Patients With HF-Associated Pleural Effusion
| Chloride (mEq/L) | Sodium (mEq/L) | Potassium (mEq/L) | |||||||
|---|---|---|---|---|---|---|---|---|---|
| Serum | PlF | PlF-serum | Serum | PlF | PlF-serum | Serum | PlF | PlF-serum | |
| 1 | 97 | 106 | 9 | 131 | 133 | 2 | 5.4 | 5.2 | −0.2 |
| 2 | 102 | 116 | 14 | 143 | 145 | 2 | 3.4 | 3.3 | −0.1 |
| 3 | 105 | 111 | 6 | 138 | 138 | 0 | 5 | 4.7 | −0.3 |
| 4 | 106 | 113 | 7 | 144 | 145 | 1 | 4.1 | 4 | −0.1 |
| 5 | 103 | 110 | 7 | 137 | 138 | 1 | 3.9 | 3.8 | −0.1 |
| 6 | 114 | 118 | 4 | 139 | 141 | 2 | 4.2 | 4.3 | 0.1 |
| 7 | 95 | 101 | 6 | 128 | 132 | 4 | 5.7 | 5.7 | 0 |
| 8 | 96 | 101 | 5 | 135 | 135 | 0 | 4 | 4.1 | 0.1 |
| 9 | 106 | 114 | 8 | 139 | 141 | 2 | 3.9 | 3.8 | −0.1 |
| 10 | 100 | 107 | 7 | 139 | 138 | −1 | 4.5 | 3.7 | −0.8 |
| 11 | 97 | 108 | 11 | 137 | 137 | 0 | 4.3 | 3.9 | −0.4 |
| 12 | 111 | 115 | 4 | 144 | 144 | 0 | 4.2 | 4.1 | −0.1 |
| 13 | 106 | 113 | 7 | 143 | 143 | 0 | 3.6 | 3.8 | 0.2 |
| 14 | 104 | 113 | 9 | 140 | 141 | 1 | 4.2 | 4.4 | 0.2 |
| 15 | 110 | 117 | 7 | 146 | 145 | −1 | 4.2 | 4 | −0.2 |
| 104±5.7 | 111±5.3 | 7.4±2.6 | 139±4.9 | 140±4.3 | 0.9±1.4 | 4.3±0.6 | 4.2±0.6 | −0.1±0.3 | |
HF, heart failure; PlF, pleural fluid.
Figure.Effusion-serum electrolyte gradient in heart failure-associated pleural effusion. The effusion-serum electrolyte gradient was selectively and significantly higher for chloride than for sodium and potassium concentrations. Symbols show values for individual patients, with the horizontal lines indicating mean values and whiskers indicating the standard deviation.
Electrolyte Concentrations in Pleural/Interstitial Fluids Compared With Blood Serum Under Normal Physiological Conditions and in Heart Failure
| Pleural space | Reference | Interstitial space | Reference | |
|---|---|---|---|---|
| Normal physiology | ||||
| Sodium | Lower | Sahn et al, | Lower | Edelman et al |
| Chloride | Lower | Zocchi et al | Higher | |
| Potassium | Equivalent | Lower | ||
| Heart failure | ||||
| Sodium | Slightly higher | Present study | Unclear | Not available |
| Chloride | Selectively and greatly higher | |||
| Potassium | Equivalent | |||